EUREKA THERAPEUTICS ANNOUNCES INITIATION OF PHASE I/II ARYA-3 CLINICAL TRIAL OF GPC3 TARGETING ARTEMIS® T CELL THERAPY IN LIVER CANCER
Excerpt from the Press Release:
Emeryville, California, July 21, 2021 — Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS® T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer. The Phase I portion of the ARYA-3 study is now open for enrollment.
Glypican 3 (GPC3) is a promising target for HCC therapies and is found in more than 70% of HCC cells. The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer. During the ECT204 ARYA-3 investigational study, a patient’s T cells will be collected, engineered to express Eureka’s proprietary ARTEMIS® cell receptors targeting GPC3, and infused back into the patient’s body to target and kill GPC3-expressing cancer cells.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?